Management of Testosterone Therapy in FTM Patients with Erythrocytosis

Understanding the Risk Profile

The American College of Physicians and other medical societies suggest that erythrocytosis is the most common dose-limiting adverse effect of testosterone therapy, occurring with significantly different frequencies based on formulation 1, 2
Injectable testosterone is associated with a 43.8% development of elevated hematocrit (>52%) 1, 2
Transdermal patches are associated with a 15.4% development of elevated hematocrit 1, 2
Testosterone gel (low dose) is associated with a 2.8-11.3% development of erythrocytosis 1

Elevation of hematocrit above normal range may have grave consequences, particularly since increased blood viscosity can aggravate vascular disease in coronary, cerebrovascular, or peripheral circulation 2, 3
The American Heart Association recommends that patients with pre-existing conditions like chronic obstructive pulmonary disease should be monitored closely for erythrocytosis 1, 2

When hematocrit exceeds 54%, intervention is mandatory, including temporary discontinuation of testosterone therapy, therapeutic phlebotomy or blood donation, and consideration of dose reduction 1, 2, 4
The Endocrine Society recommends adjusting dosing to achieve total testosterone levels in the middle tertile of normal range (450-600 ng/dL) 5, 6

The American College of Physicians recommends measuring hemoglobin/hematocrit at baseline and monitoring during therapy, with most intensive surveillance in the first year 4
Most hematocrit changes occur in the first 3 months, and baseline hematocrit >50% warrants investigation before initiating therapy 1, 3, 4

The American College of Physicians recommends advising smoking cessation, as tobacco use increases the odds of erythrocytosis by 2.2-fold, although the exact odds ratio is not specified in the provided citations 7, 8
The Endocrine Society suggests switching to transdermal administration, as injectable testosterone is associated with a 43.8% incidence of elevated hematocrit (>52%), compared to 15.4% with transdermal patches and 2.8-11.3% with testosterone gel, with moderate evidence strength 9
The American Heart Association recommends weight loss if BMI is elevated, as high BMI increases the odds of erythrocytosis by 3.7-fold, with low-to-moderate evidence strength 7, 8

The European Association of Urology suggests reducing testosterone dosing to achieve levels in the middle tertile of normal range (450-600 ng/dL), with low evidence strength 10

The American College of Cardiology warns that elevation of hematocrit above normal range may have grave consequences, particularly in elderly patients, since increased blood viscosity can aggravate vascular disease in coronary, cerebrovascular, or peripheral circulation, with high evidence strength 9

The American College of Physicians and other guideline societies recommend monitoring hemoglobin/hematocrit at baseline, 1-2 months after any change, every 3-6 months during the first year, then annually, as most hematocrit changes occur in the first 3 months 11
Monitoring for sleep apnea is crucial, as testosterone can exacerbate this condition, which is a risk factor for erythrocytosis 11

Smoking cessation is essential, as smoking increases erythrocytosis odds 2.2-fold, according to the American Heart Association 11
Weight loss is recommended if BMI is elevated, as high BMI increases odds of erythrocytosis 3.7-fold, as suggested by the National Institutes of Health 11